Showing 21 - 30 of 2,776
In 1924, The Morton Salt Company began nationwide distribution of iodine-fortified salt. Ac- cess to iodine, a key determinant of cognitive ability, rose sharply. We compare outcomes for cohorts exposed in utero with those of slightly older, unexposed cohorts, across states with high versus low...
Persistent link: https://www.econbiz.de/10012914262
We use data from the Medicare Current Beneficiary Survey (MCBS) to document the medical spending of Americans aged 65 and older. We find that medical expenses more than double between ages 70 and 90 and that they are very concentrated: the top 10% of all spenders are responsible for 52% of...
Persistent link: https://www.econbiz.de/10013021020
branded pharmaceuticals. We then present a theoretical framework for the pricing of branded pharmaceuticals, without and then …
Persistent link: https://www.econbiz.de/10013139118
We examine the impact of loss of U.S. patent exclusivity (LOE) on the prices and utilization of specialty drugs between 2001 and 2007. We limit our empirical cohort to drugs commonly used to treat cancer and base our analyses on nationally representative data from IMS Health. We begin by...
Persistent link: https://www.econbiz.de/10013056202
The support for scientific investigation in biomedicine depends in part on the adoption of new knowledge into medical practice. We investigate how a technological advance, in the form of a large and influential 2010 randomized controlled study, changed physician practice in statin (a medication...
Persistent link: https://www.econbiz.de/10012863696
Throughout history, technological progress has transformed population health, but the distributional effects of these gains are unclear. New substitutes for older, more expensive health technologies can produce convergence in population health outcomes, but may also be prone to “elite...
Persistent link: https://www.econbiz.de/10012893126
We hypothesize that pharmaceutical-embodied technical progress increases per capita output via its effect on labor supply (the employment rate and hours worked per employed person). We examine the effect of changes in both the average quantity and average vintage (FDA approval year) of drugs...
Persistent link: https://www.econbiz.de/10013222635
Rapid technological progress has been a defining feature of the medical sector over the last century, yet we know little about the determinants of the development of these new technologies. This paper examines whether and to what extent the demand-side incentives embodied in health policy affect...
Persistent link: https://www.econbiz.de/10013229048
Persistent link: https://www.econbiz.de/10001222733
Persistent link: https://www.econbiz.de/10001233954